Edward Tenthoff

Stephen Willey

David Bautz

Swayampakula Ramakanth

Kristen Kluska

Ayan Hussein

Douglas Macpherson

Leah Rush Cann

- X4 Pharmaceuticals announced the **closing of its previously announced underwritten public offering** on **October 27, 2025**.  **[1501697_a4181cecdf154c768a3bb39ef71a0fa6_0]** 
- The offering included **52,844,000 shares of common stock** at a public offering price of **$2.90 per share** and **700,000 pre-funded warrants** at **$2.899 per pre-funded warrant**.  **[1501697_a4181cecdf154c768a3bb39ef71a0fa6_0]** 
- The aggregate gross proceeds to X4 from the offering were **approximately $155.3 million**.  **[1501697_a4181cecdf154c768a3bb39ef71a0fa6_0]** 
- After giving effect to the offering, the total shares outstanding for X4 Pharmaceuticals are **79,214,708**.  **[1501697_a4181cecdf154c768a3bb39ef71a0fa6_0]**

X4 Pharmaceuticals Announces Closing of Public Offering

- X4 Pharmaceuticals, Inc. entered into an underwriting agreement on **October 23, 2025**, to sell **45,860,000** shares of common stock at **$2.90** per share and pre-funded warrants to purchase **700,000** shares at **$2.899** per share.  **[1501697_0001501697-25-000032_xfor-20251023.htm:1]** **[1501697_0001501697-25-000032_ex11oct2025underwritingagr.htm:43]** 
- The underwriters fully exercised their option on **October 24, 2025**, to purchase an additional **6,984,000** shares of common stock.  **[1501697_0001501697-25-000032_xfor-20251023.htm:1]** 
- The company expects to receive approximately **$145.6 million** in net proceeds from the offering, which is anticipated to close on **October 27, 2025**.  **[1501697_0001501697-25-000032_xfor-20251023.htm:1]**

X4 Pharmaceuticals, Inc. Announces Public Offering of Common Stock and Warrants

- X4 Pharmaceuticals (XFOR) announced the pricing of an underwritten public offering of **45,860,000** shares of common stock at **$2.90** per share and pre-funded warrants to purchase up to **700,000** shares at **$2.899** per pre-funded warrant.  **[1501697_311b86b27ed4423cae1edfe33953e619_0]** 
- The offering is expected to generate approximately **$135 million** in aggregate gross proceeds before deductions and is anticipated to close on **October 27, 2025**.  **[1501697_311b86b27ed4423cae1edfe33953e619_0]** 
- The net proceeds from this offering will be used to fund the pivotal Phase 3 development of mavorixafor in certain chronic neutropenic disorders, as well as for general and administrative expenses, capital expenditures, working capital, and other general corporate purposes.  **[1501697_311b86b27ed4423cae1edfe33953e619_0]** 
- The underwriters have been granted a 30-day option to purchase up to an additional **6,984,000** shares of common stock.  **[1501697_311b86b27ed4423cae1edfe33953e619_0]**

X4 Pharmaceuticals Prices $135 Million Public Offering

- **X4 Pharmaceuticals announced a strategic restructuring** on September 17, 2025, which includes a **50% reduction in its workforce**.  **[1501697_0001501697-25-000021_ex991_2025916release.htm:0]** **[1501697_0001501697-25-000021_xfor-20250915.htm:1]** 
- This initiative is anticipated to generate **annualized cost savings of approximately $13 million**.  **[1501697_0001501697-25-000021_ex991_2025916release.htm:0]** **[1501697_0001501697-25-000021_xfor-20250915.htm:1]** 
- The company estimates it will incur **cash charges of approximately $3.3 million** for severance and other employee termination-related costs, with the workforce reduction substantially completed in the third quarter of 2025.  **[1501697_0001501697-25-000021_xfor-20250915.htm:1]** 
- As part of the restructuring, **John Volpone was appointed Chief Operating Officer** in addition to his role as President, while the **former Chief Operating Officer, Chief Commercial Officer, Chief Legal & Compliance Officer, and Chief Medical Officer are exiting** the company.  **[1501697_0001501697-25-000021_ex991_2025916release.htm:0]** **[1501697_0001501697-25-000021_xfor-20250915.htm:2]**